Rapallo A, Sciutto A, Geido E, Orecchia R, Infusini E, Pujic N, d'Amore E S, Monaco R, Risio M, Rossini F P, Giaretti W
Laboratory of Biophysics and Cytometry, National Cancer Institute, Genoa, Italy.
Anal Cell Pathol. 1999;19(1):39-46. doi: 10.1155/1999/257265.
The possible role of K-ras2 mutations and aneuploidy toward increase of proliferation and adenoma size in Familial Adenomatous Polyposis (FAP) adenomas is not known. The present study addresses these issues by investigating 147 colorectal adenomas obtained from four FAP patients. The majority of adenomas had size lower than or equal to 10 mm (86%), low grade dysplasia (63%), and were preferentially located in the right colon (60%). Normal mucosa samples were obtained from 19 healthy donors. Three synchronous adenocarcinomas were also investigated. K-ras2 mutation spectrum was analysed by PCR and Sequence Specific Oligonucleotide (SSO) hybridization, while flow cytometry (FCM) was used for evaluating degree of DNA ploidy and S-phase fraction. Overall, incidences of K-ras2 mutations, DNA aneuploidy and high S-phase values (>7.2%) were 6.6%, 5.4% and 10.5%, respectively. In particular, among the adenomas with size lower than 5 mm, K-ras2 mutation and DNA aneuploidy frequencies were only slightly above 1%. Statistically significant correlations were found between K-ras2 and size, DNA ploidy and size and K-ras2 and S-phase (p < 0.001). In particular, among the wild type K-ras2 adenomas, high S-phase values were detected in 8% of the cases versus 57% among the K-ras2 mutated adenomas (p = 0.0005). The present series of FAP adenomas indicates that K-ras2 activation and gross genomic changes play a role toward a proliferative gain and tumour growth in size.
K-ras2突变和非整倍体在家族性腺瘤性息肉病(FAP)腺瘤中对增殖增加和腺瘤大小的影响尚不清楚。本研究通过调查从4例FAP患者获得的147个大肠腺瘤来探讨这些问题。大多数腺瘤大小小于或等于10mm(86%),低级别发育异常(63%),且多位于右半结肠(60%)。从19名健康供体获取正常黏膜样本。还对3例同时性腺癌进行了研究。通过聚合酶链反应(PCR)和序列特异性寡核苷酸(SSO)杂交分析K-ras2突变谱,同时采用流式细胞术(FCM)评估DNA倍体程度和S期分数。总体而言,K-ras2突变、DNA非整倍体和高S期值(>7.2%)的发生率分别为6.6%、5.4%和10.5%。特别是,在大小小于5mm的腺瘤中,K-ras2突变和DNA非整倍体频率仅略高于1%。发现K-ras2与大小、DNA倍体与大小以及K-ras2与S期之间存在统计学显著相关性(p<0.001)。特别是,在野生型K-ras2腺瘤中,8%的病例检测到高S期值,而在K-ras2突变腺瘤中这一比例为57%(p=0.0005)。本系列FAP腺瘤表明,K-ras2激活和总体基因组变化在增殖增加和肿瘤大小增长方面发挥作用。